Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Academic Article uri icon

Overview

MeSH

  • Animals
  • Apoptosis
  • Cell Proliferation
  • Gene Expression Regulation
  • Genes, Transgenic, Suicide
  • Genetic Engineering
  • Genetic Vectors
  • Humans

MeSH Major

  • Cell Differentiation
  • Neoplastic Stem Cells
  • Pluripotent Stem Cells
  • Stem Cell Transplantation
  • Transplantation Conditioning

abstract

  • The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.

publication date

  • April 3, 2009

has subject area

  • Animals
  • Apoptosis
  • Cell Differentiation
  • Cell Proliferation
  • Gene Expression Regulation
  • Genes, Transgenic, Suicide
  • Genetic Engineering
  • Genetic Vectors
  • Humans
  • Neoplastic Stem Cells
  • Pluripotent Stem Cells
  • Stem Cell Transplantation
  • Transplantation Conditioning

Research

keywords

  • Journal Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3254150

Digital Object Identifier (DOI)

  • 10.1016/j.stem.2009.03.010

PubMed ID

  • 19341619

Additional Document Info

start page

  • 289

end page

  • 300

volume

  • 4

number

  • 4